Objective. To correlate the quality of life and clinical severity of psoriasis vulgaris in patients using different types of treatment. Psoriasis is found worldwide but the prevalence varies among different ethnic groups. The epidemiology, clinical features, and impact on quality of life of psoriasis are reviewed. Patients with early onset, or type I psoriasis, tended to have more relatives affected and more severe disease than patients who have a later onset of disease or type II psoriasis. Psoriasis can be highly variable in morphology, distribution, and severity. Patients with moderate to severe psoriasis generally require phototherapy (e. Psoriasis: correlation between clinical severity (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment.
Treatment satisfaction among moderate-to-severe psoriasis patients has not been studied and compared across treatments using a validated instrument. To assess patient-reported satisfaction with systemic and phototherapy treatments for moderate-to-severe psoriasis in clinical practice and to correlate satisfaction with disease severity and quality of life measures. Cross-sectional study of 1182 patients with moderate-to-severe psoriasis in the Dermatology Clinical Effectiveness Research Network in the United States. 01), we conducted sensitivity analyses by further adjusting each model for these two variables among patients receiving treatments other than topical therapies only. Factors associated with quality of life in psoriasis patients are described. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis (1998) 50. The scale has been validated and correlates with other measures of subjective well-being (SWB). Severity of psoriasis was associated with a marked impact on quality of life. On average, patients had received other treatments, such as conventional systemic treatments or phototherapy, for more than 2 years before switching to biologic agents for the first time. 22.3 phototherapy, and 24.6 (n107) another type of treatment (Fig. 7,15 Our findings with regard to age are consistent with those reported in a systemic review of quality of life in psoriasis in that higher age was correlated with a better quality of life.7 In agreement with other reports,20 we did not detect significant differences in quality of life between patients with psoriasis and psoriatic arthritis and those with psoriasis alone.
(1999) found that in patients with psoriasis the impaired physical and mental functioning was comparable to that seen in cancer, arthritis, hypertension, heart disease, diabetes, and depression. Keeping patient’s QoL in mind may also have an influence on the decision of treatment in the clinical routine and consecutive on patient’s compliance. Quality of life and disease severity in children may be correlated (Ben-Gashir et al. (2002) found in comparing psoriasis with other chronic skin disorders (acne vulgaris, atopic dermatitis, viral and fungal infection, sun-damaged skin and different types of eczema) patients with psoriasis suffer more from experiences of stigmatization than a control group consisting of patients with mixed different other dermatologic diseases. By Frederico Teixeira and Petronila Rocha-pereira in Quality of life and Dermatology. Health-related quality of life in Portuguese psoriatic patients: relation with Psoriasis Area and Severity Index and different types of classical psoriatic treatment. The distribution of psoriasis medication costs and the quality of life in these patients has been estimated to be around 20 of total costs. It has been suggested that patients with severe Ps should be treated more with systemic medications 9. Clinical information was collected from the 236 patients’ medical records who gave consent, for the same time period that was covered in the questionnaire data. To analyze how many different types of treatments each patient used, treatment options were formed as following.
Patient Satisfaction With Treatments For Moderate-to-severe Plaque Psoriasis In Clinical Practice
Article: Quality Of Life of Patients with Neurodermatitis. The diagnosis of psoriasis is clinical, and the type of psoriasis present affects the physical examination findings. Chronic stationary psoriasis (psoriasis vulgaris): Most common type of psoriasis; involves the scalp, extensor surfaces, genitals, umbilicus, and lumbosacral and retroauricular regions. Laboratory studies and findings for patients with psoriasis may include the following:. Other studies. A 2013 international consensus report on treatment optimization and transitioning for moderate-to-severe plaque psoriasis include the following recommendations 3:. Usually, psoriasis severity is clinically evaluated using tools like Psoriasis Area and Severity Index that present some limitations and subjectivity. As any attempt to identify these biomarkers should be encouraged, in this review, we will debate published data concerning the proposal of biomarkers to evaluate severity and response to treatment of psoriasis vulgaris. An assessment of any patient with psoriasis should include disease severity, the impact of disease on physical, psychological and social well-being, whether they have psoriatic arthritis, and the presence of any comorbidities. Tools such as the Dermatology Life Quality Index may be helpful. As such, Chinese patients with psoriasis can receive effective, safe, and individualized treatment. Epidemiology and treatment of psoriasis: a Chinese perspective Ran Pan, Jianzhong Zhang Department of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of China Background: Psoriasis is a chronic inflammatory skin disease that has a negative impact on quality of life. Table 2 Different types of psoriasis identified in Chinese and Japanese studies. Moderate and severe psoriasis are treated with combined topical and systemic therapy. In patients with chronic plaque psoriasis treated with systemic biologic therapy, systemic nonbiologic therapy, or phototherapy, which patient or disease characteristics (e., age, gender, race, weight, smoking status, psoriasis severity, presence or absence of concomitant psoriatic arthritis, disease duration, baseline disease severity, affected BSA, disease location, number and type of previous treatments, failure of previous treatments and presence of neutralizing antibodies) affect intermediate and final outcomes?. In an RCT that compared the efficacy and safety of adalimumab with placebo in patients with moderate to severe plaque psoriasis, investigators sought to correlate various measures of HRQoL to clinical outcomes.31 DLQI was moderately correlated with PASI (r 0.